NASDAQ
Kymera Therapeutics, Inc. (KYMR)
♥ 511 Thanks from members
Kymera Therapeutics (KYMR) exhibits strong positive market sentiment driven by robust Q2 2026 collaboration revenues, an expanded $1.5 billion cash runway into 2029, and accelerated Phase 2b enrollment for its oral STAT6 degrader KT-621.